{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T07:14:16Z","timestamp":1760426056141},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>The objective of the study is to explore the long-term effectiveness and tolerability of metoclopramide in the treatment of CIH.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>This study is a retrospective, observational cohort study of patients prescribed metoclopramide for CIH at the South London &amp; Maudsley (SLaM) NHS Foundation Trust.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 96 patients identified, 14 patients were eligible for inclusion in our study. Five patients continued treatment with a mean duration of 27\u00a0months (SD\u2009=\u200917.8), and one patient continued until transfer with a duration of 3\u00a0months. Eight patients discontinued treatment after a mean duration of 8\u00a0months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Metoclopramide may be an effective and tolerated drug in CIH, but more data is required to establish its place in the pharmacotherapy of this condition.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-022-03940-0","type":"journal-article","created":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T09:05:53Z","timestamp":1650445553000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A retrospective case notes review of the effectiveness and tolerability of metoclopramide in the treatment of clozapine-induced hypersalivation (CIH)"],"prefix":"10.1186","volume":"22","author":[{"given":"Cecilia","family":"Livermore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loren","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Osborne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ebenezer","family":"Oloyede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olubanke","family":"Dzahini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eromona","family":"Whiskey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,20]]},"reference":[{"key":"3940_CR1","unstructured":"British National Formulary (2021). Metoclopramide hydrochloride. [online] NICE. Available at: https:\/\/bnf.nice.org.uk\/drug\/metoclopramide-hydrochloride.html [Accessed 19 May 2021]."},{"issue":"5","key":"3940_CR2","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/bja\/83.5.761","volume":"83","author":"I Henzi","year":"1999","unstructured":"Henzi I, Walder B, Tramer MR. Metoclopramide in the prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized, placebo-controlled studies. Br J Anaesth. 1999;83(5):761\u201371.","journal-title":"Br J Anaesth"},{"key":"3940_CR3","unstructured":"Martindale (2021). Digital Medicines Information Suite - metoclopramide. [online] MedicinesComplete.\u00a0Available at:\u00a0https:\/\/www.medicinescomplete.com\/#\/content\/martindale\/11464-n#content%2Fmartindale%2F11464-n%2311464-n\u00a0[Accessed 19 May 2021]."},{"issue":"3","key":"3940_CR4","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1097\/JCP.0000000000000493","volume":"36","author":"A Kreinin","year":"2016","unstructured":"Kreinin A, Miodownik C, Mirkin V, Gaiduk Y, Yankovsky Y, Bersudsky Y, Lerner PP, Bergman J, Lerner V. Double-Blind, Randomized, Placebo-Controlled Trial of Metoclopramide for Hypersalivation Associated With Clozapine. J Clin Psychopharmacol. 2016;36(3):200\u20135.","journal-title":"J Clin Psychopharmacol"},{"key":"3940_CR5","unstructured":"EMC (2020). Zaponex 100 mg Tablets - Summary of Product Characteristics (SmPC) - (emc). [online] www.medicines.org.uk. Available at: https:\/\/www.medicines.org.uk\/emc\/product\/7715\/smpc#UNDESIRABLE_EFFECTS [Accessed 19 May 2021]."},{"issue":"1\u20133","key":"3940_CR6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.schres.2016.05.002","volume":"174","author":"SE Legge","year":"2016","unstructured":"Legge SE, Hamshere M, Hayes RD, Downs J, O\u2019Donovan MC, Owen MJ, MacCabe JH. Reasons for discontinuing clozapine: a cohort study of patients commencing treatment. Schizophr Res. 2016;174(1\u20133):113\u20139.","journal-title":"Schizophr Res"},{"issue":"3","key":"3940_CR7","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s00213-005-0248-4","volume":"185","author":"SK Praharaj","year":"2006","unstructured":"Praharaj SK, Arora M, Gandotra S. Clozapine-induced sialorrhea: pathophysiology and management strategies. Psychopharmacology. 2006;185(3):265\u201373.","journal-title":"Psychopharmacology"},{"key":"3940_CR8","unstructured":"NICE (2013). Intervention and alternatives | Hypersalivation: oral glycopyrronium bromide | Advice | NICE. [online] www.nice.org.uk. Available at: https:\/\/www.nice.org.uk\/advice\/esuom15\/chapter\/intervention-and-alternatives [Accessed 19 May 2021]."},{"key":"3940_CR9","doi-asserted-by":"publisher","unstructured":"Syed R, Au K, Cahill C, Duggan L, He Y, Udu V, Xia J. Pharmacological interventions for clozapine-induced hypersalivation. Cochrane Database Syst Rev. 2008;(3):CD005579. https:\/\/doi.org\/10.1002\/14651858.CD005579.pub2.","DOI":"10.1002\/14651858.CD005579.pub2"},{"issue":"3","key":"3940_CR10","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s40263-019-00612-8","volume":"33","author":"SY Chen","year":"2019","unstructured":"Chen SY, Ravindran G, Zhang Q, Kisely S, Siskind D. Treatment strategies for clozapine-induced sialorrhea: a systematic review and meta-analysis. CNS Drugs. 2019;33(3):225\u201338.","journal-title":"CNS Drugs"},{"key":"3940_CR11","unstructured":"EMC (2020). Metoclopramide 10mg Tablets - Summary of Product Characteristics (SmPC) - (emc). [online] www.medicines.org.uk. Available at: https:\/\/www.medicines.org.uk\/emc\/product\/5880\/smpc."},{"issue":"1","key":"3940_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1365-2036.2009.04189.x","volume":"31","author":"AS Rao","year":"2010","unstructured":"Rao AS, Camilleri M. metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010;31(1):11\u20139.","journal-title":"Aliment Pharmacol Ther"},{"key":"3940_CR13","volume-title":"European Medicines Agency recommends changes to the use of metoclopramide","author":"EMA","year":"2013","unstructured":"EMA. European Medicines Agency recommends changes to the use of metoclopramide. 2013. (https:\/\/www.ema.europa.eu\/en\/documents\/referral\/metoclopramide-article-31-referral-european-medicines-agency-confirms-changes-use-metoclopramide_en.pdf Accessed 19 May 2021)."},{"issue":"11","key":"3940_CR14","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/S0006-3223(96)89255-9","volume":"40","author":"T Rabinowitz","year":"1996","unstructured":"Rabinowitz T, Frankenburg FR, Centorrino F, Kando J. The effect of clozapine on saliva flow rate: A pilot study. Biol Psychiat. 1996;40(11):1132\u20134.","journal-title":"Biol Psychiat"},{"key":"3940_CR15","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1002\/ccr3.2431","volume":"7","author":"T Van der Poorten","year":"2019","unstructured":"Van der Poorten T, et al. The sublingual use of atropine in the treatment of clozapine-induced sialorrhea: a systematic review. Clin Case Rep. 2019;7:2108\u201313.","journal-title":"Clin Case Rep"},{"key":"3940_CR16","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1192\/pb.25.7.277-c","volume":"25","author":"JP McKane","year":"2001","unstructured":"McKane JP, et al. Hyoscine patches in clozapine-induced hypersalivation. Psychiatr Bull. 2001;25:277.","journal-title":"Psychiatr Bull"},{"key":"3940_CR17","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/S0140-6736(95)91713-6","volume":"346","author":"J Fritze","year":"1995","unstructured":"Fritze J, et al. Pirenzepine for clozapine-induced hypersalivation. Lancet. 1995;346:1034.","journal-title":"Lancet"},{"key":"3940_CR18","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/j.pnpbp.2007.06.013","volume":"31","author":"HS Duggal","year":"2007","unstructured":"Duggal HS. Glycopyrrolate for clozapine-induced sialorrhea. Prog Neuropsychopharmacol Boil Psychiatry. 2007;31:1546\u20137.","journal-title":"Prog Neuropsychopharmacol Boil Psychiatry"},{"key":"3940_CR19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1136\/ebmh.12.1.12","volume":"12","author":"S Sockalingam","year":"2009","unstructured":"Sockalingam S, et al. Review: Insufficient evidence to guide use of drugs for clozapine induced hypersalivation. Evid Based Ment Health. 2009;12:12.","journal-title":"Evid Based Ment Health"},{"issue":"2","key":"3940_CR20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/01.yic.0000188216.92408.69","volume":"21","author":"A Kreinin","year":"2006","unstructured":"Kreinin A, Novitski D, Weizman A. Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study. Int Clin Psychopharmacol. 2006;21(2):99\u2013103.","journal-title":"Int Clin Psychopharmacol"},{"key":"3940_CR21","unstructured":"Beersheva Mental Health Center (2014). Clinical Trial on Clozapine-induced Hypersalivation: Metoclopramide, placebo - Clinical Trials Registry - ICH GCP. [online] ichgcp.net. Available at: https:\/\/ichgcp.net\/clinical-trials-registry\/NCT02222220 [Accessed 19 May 2021]."},{"issue":"2","key":"3940_CR22","first-page":"106","volume":"26","author":"S Gupta","year":"2019","unstructured":"Gupta S, Khastgir U, Croft M, Roshny S. Management of clozapine-induced sialorrhoea. BJPsych. Advances. 2019;26(2):106\u20138.","journal-title":"Advances"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-022-03940-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-022-03940-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-022-03940-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T12:09:21Z","timestamp":1650542961000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-022-03940-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,20]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3940"],"URL":"https:\/\/doi.org\/10.1186\/s12888-022-03940-0","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,20]]},"assertion":[{"value":"19 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a retrospective case notes review, so informed consent was not required for data collection for this study by our institution. All methods were performed in accordance with relevant guidelines and regulations. The study was approved by the South London & Maudsley (SLaM) NHS Foundation Trusts\u2019 Drugs and Therapeutics Committee (DTC\/2020\/105), the locally designated ethical approval committee for all noninterventional prescribing outcome evaluations. Informed consent for the current study is waived by SLaM Drug and Therapeutics Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"277"}}